Celltrion Inc. announced on Tuesday that the prescription preference for its Remsima SC (infliximab) subcutaneous injection is on the rise in key European countries.

According to pharmaceutical market research firm IQVIA, Remsima SC and Remsima intravenous (IV) formulation, both biosimilars for autoimmune disease treatments, accounted for 74 percent of the market share in five major European countries in the fourth quarter of last year.

The five countries make up 60 percent of the infliximab market.

Celltrion attributed the increase in its market share to the dual formulation effect, where Remsima SC, introduced in 2020, replaced Remsima IV.

This strategy led to a cumulative increase of 12 percentage points in market share over the three years since the launch of Remsima SC.

Celltrion’s cancer drugs, Vegzelma and Herzuma, also recorded market shares of 9 percent and 19 percent in Europe in the fourth quarter of last year, up 9 and 4 percentage points, respectively, compared to the previous year.

Another biosimilar Yuflyma, also for autoimmune disease treatment, saw its market share up by 6 percentage points to reach 7 percent during the same period.

Celltrion highlighted that these results were achieved through tailored sales and marketing strategies and bidding plans pursued across its 16 entities in Europe.

By Pulse

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]